Remove Blogging Remove Capital Remove Doc Remove Study
article thumbnail

Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More

Xconomy

Nearly four years after investors snapped up new shares of Juno Therapeutics in a $265 million IPO, cancer immunotherapy remains a hot ticket. Like Juno, Allogene Therapeutics just pulled in a massive IPO haul, nearly $300 million.

Doc 74